ECSP088850A - Formulación de medicamento líquida - Google Patents

Formulación de medicamento líquida

Info

Publication number
ECSP088850A
ECSP088850A EC2008008850A ECSP088850A ECSP088850A EC SP088850 A ECSP088850 A EC SP088850A EC 2008008850 A EC2008008850 A EC 2008008850A EC SP088850 A ECSP088850 A EC SP088850A EC SP088850 A ECSP088850 A EC SP088850A
Authority
EC
Ecuador
Prior art keywords
formulation
medicinal product
liquid medicinal
liquid
animals
Prior art date
Application number
EC2008008850A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Gerald Beddies
Georg Schulte
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP088850A publication Critical patent/ECSP088850A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una formulación de medicamento líquida para betabloqueantes que es especialmente adecuada para la administración por vía oral en animales.
EC2008008850A 2006-05-02 2008-10-29 Formulación de medicamento líquida ECSP088850A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006020604A DE102006020604A1 (de) 2006-05-02 2006-05-02 Flüssige Arzneimittelformulierung

Publications (1)

Publication Number Publication Date
ECSP088850A true ECSP088850A (es) 2008-12-30

Family

ID=38180418

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008850A ECSP088850A (es) 2006-05-02 2008-10-29 Formulación de medicamento líquida

Country Status (23)

Country Link
US (1) US20090264535A1 (es)
EP (1) EP2015728A2 (es)
JP (1) JP2009535368A (es)
KR (1) KR20090014183A (es)
CN (1) CN101431981A (es)
AR (1) AR060730A1 (es)
AU (1) AU2007245911A1 (es)
BR (1) BRPI0711140A2 (es)
CA (1) CA2650786A1 (es)
CO (1) CO6180495A2 (es)
CR (1) CR10407A (es)
DE (1) DE102006020604A1 (es)
EC (1) ECSP088850A (es)
GT (1) GT200800235A (es)
IL (1) IL195034A0 (es)
MX (1) MX2008013873A (es)
PE (1) PE20080149A1 (es)
RU (1) RU2008147216A (es)
SV (1) SV2008003080A (es)
TW (1) TW200808373A (es)
UY (1) UY30315A1 (es)
WO (1) WO2007124869A2 (es)
ZA (1) ZA200809269B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083177A1 (en) * 2007-12-27 2009-07-09 Bayer Animal Health Gmbh TREATMENT OF HEART DISEASE USING β-BLOCKERS
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
KR20150120008A (ko) * 2014-04-16 2015-10-27 씨제이헬스케어 주식회사 비소프롤롤 및 로수바스타틴을 포함하는 경구용 약제학적 복합제제
CN107666913B (zh) 2015-03-03 2021-11-26 萨尼奥纳有限责任公司 特索芬辛，β-受体阻滞剂组合制剂
GB202207690D0 (en) * 2022-05-25 2022-07-06 Zentiva Ks Liquid pharmaceutical formulation of bisoprolol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4600708A (en) * 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
EP1029536B1 (en) * 1997-10-01 2007-11-28 Novadel Pharma Inc. Buccal non-polar spray
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6335335B2 (en) * 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
SV2008003080A (es) 2009-11-26
BRPI0711140A2 (pt) 2011-08-23
CN101431981A (zh) 2009-05-13
US20090264535A1 (en) 2009-10-22
WO2007124869A3 (de) 2008-04-17
WO2007124869A2 (de) 2007-11-08
CA2650786A1 (en) 2007-11-08
GT200800235A (es) 2010-04-28
AR060730A1 (es) 2008-07-10
RU2008147216A (ru) 2010-06-10
ZA200809269B (en) 2009-12-30
KR20090014183A (ko) 2009-02-06
JP2009535368A (ja) 2009-10-01
CO6180495A2 (es) 2010-07-19
MX2008013873A (es) 2008-11-14
TW200808373A (en) 2008-02-16
AU2007245911A1 (en) 2007-11-08
UY30315A1 (es) 2007-11-30
CR10407A (es) 2009-03-30
IL195034A0 (en) 2009-08-03
EP2015728A2 (de) 2009-01-21
DE102006020604A1 (de) 2007-11-08
PE20080149A1 (es) 2008-04-06

Similar Documents

Publication Publication Date Title
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
DOP2011000218A (es) Derivados de sulfonamida
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
CO6321158A2 (es) Formulacion oral
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
ECSP088850A (es) Formulación de medicamento líquida
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
BR112015014993A2 (pt) composição para higiene oral
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
SV2008003018A (es) Formulaciones medicamentosas que contienen fluoroquinolonas
CR11734A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BRPI0923675A2 (pt) formulação para administração de medicamento com baixa quantidade de lipídeos por via transmucosal oral
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina